Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and ...

Dupixent (dupilumab) is tipped to be the market ... Sanofi says there has been more than 200 applications to receive the drug under the system, which ceases once a drug gains marketing approval.

Monday closed down -2.70%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -2.08%, and the Nasdaq 100 Index ($IUXX) ...

The stock has a fifty day moving average price of $52.65 and a 200 day moving average price ... The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases ...

The 10-year T-note yield fell -10.1 bp to 4.200%. June T-notes rallied Monday ... Nasdaq 100 after it said a late-stage trial of its Dupixent to treat a rare skin disorder met all main goals.

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

The company is advancing around 40 of its programs. It has relied on two primary products to drive top-line growth in the past years: Dupixent and Eylea. Dupixent is an eczema treatment whose ...